EP1326627A4 - Verfahren zur modulation der apoptose durch anwendung von relaxin-agonisten oder antagonisten - Google Patents
Verfahren zur modulation der apoptose durch anwendung von relaxin-agonisten oder antagonistenInfo
- Publication number
- EP1326627A4 EP1326627A4 EP01979945A EP01979945A EP1326627A4 EP 1326627 A4 EP1326627 A4 EP 1326627A4 EP 01979945 A EP01979945 A EP 01979945A EP 01979945 A EP01979945 A EP 01979945A EP 1326627 A4 EP1326627 A4 EP 1326627A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- antagonists
- administration
- methods
- modulating apoptosis
- relaxin agonists
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000003743 Relaxin Human genes 0.000 title 1
- 108090000103 Relaxin Proteins 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 230000006907 apoptotic process Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/64—Relaxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2221—Relaxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Pregnancy & Childbirth (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23823200P | 2000-10-04 | 2000-10-04 | |
US238232P | 2000-10-04 | ||
US24199100P | 2000-10-20 | 2000-10-20 | |
US24203700P | 2000-10-20 | 2000-10-20 | |
US241991P | 2000-10-20 | ||
US242037P | 2000-10-20 | ||
PCT/US2001/042484 WO2002028418A1 (en) | 2000-10-04 | 2001-10-04 | Methods of modulating apoptosis by administration of relaxin agonists or antagonists |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1326627A1 EP1326627A1 (de) | 2003-07-16 |
EP1326627A4 true EP1326627A4 (de) | 2004-06-16 |
Family
ID=27399064
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP01979945A Withdrawn EP1326627A4 (de) | 2000-10-04 | 2001-10-04 | Verfahren zur modulation der apoptose durch anwendung von relaxin-agonisten oder antagonisten |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1326627A4 (de) |
JP (3) | JP2004510743A (de) |
AU (2) | AU1185502A (de) |
CA (2) | CA2967607A1 (de) |
IL (1) | IL155250A0 (de) |
NZ (1) | NZ525389A (de) |
WO (1) | WO2002028418A1 (de) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040006205A1 (en) * | 2001-04-03 | 2004-01-08 | Li Li | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
US7732406B2 (en) | 2005-04-07 | 2010-06-08 | Cardiopep Pharma Gmbh | Use of natriuretic peptide for treating heart failure |
US8445635B2 (en) | 2006-04-11 | 2013-05-21 | Armour Therapeutics Inc. | Modified H2 relaxin for tumor suppression |
EP2377891B1 (de) * | 2008-12-26 | 2018-11-21 | The University of Tokyo | Diagnose und behandlung von krebs mit anti-lgr7-antikörper |
AU2014208851B2 (en) * | 2013-01-25 | 2016-12-22 | Cardiorentis Ltd. | A natriuretic peptide, a diuretic peptide or a vaso dilatory peptide for use in methods of treating cardiovascular indications |
CN113147632B (zh) * | 2021-05-17 | 2023-03-07 | 中国第一汽车股份有限公司 | 一种车辆控制方法、装置、车辆及存储介质 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH661662A5 (en) * | 1984-04-16 | 1987-08-14 | Georg L Prof Dr Floersheim | Product for the treatment of the skin and of the connective tissue |
WO1994029452A2 (en) * | 1993-06-09 | 1994-12-22 | Ribozyme Pharmaceuticals, Inc. | Enzymatic rna molecules and their application in the treatment of fibrosis and fibrous tissue disease |
WO1995007711A1 (en) * | 1993-09-14 | 1995-03-23 | Mallinckrodt Medical, Inc. | Therapeutic treatment for inhibiting blood vessel blockage using a polypeptide |
WO1999040929A1 (en) * | 1998-02-12 | 1999-08-19 | The General Hospital Corporation | Methods to potentiate cancer therapies |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5811395A (en) * | 1995-06-07 | 1998-09-22 | Medical University Of South Carolina | Relaxin analogs and derivatives methods and uses thereof |
-
2001
- 2001-10-04 CA CA2967607A patent/CA2967607A1/en not_active Abandoned
- 2001-10-04 WO PCT/US2001/042484 patent/WO2002028418A1/en active IP Right Grant
- 2001-10-04 CA CA2425712A patent/CA2425712C/en not_active Expired - Lifetime
- 2001-10-04 AU AU1185502A patent/AU1185502A/xx active Pending
- 2001-10-04 AU AU2002211855A patent/AU2002211855B2/en not_active Ceased
- 2001-10-04 NZ NZ525389A patent/NZ525389A/en not_active IP Right Cessation
- 2001-10-04 IL IL15525001A patent/IL155250A0/xx unknown
- 2001-10-04 JP JP2002532242A patent/JP2004510743A/ja not_active Withdrawn
- 2001-10-04 EP EP01979945A patent/EP1326627A4/de not_active Withdrawn
-
2008
- 2008-07-25 JP JP2008192676A patent/JP2008297313A/ja not_active Withdrawn
-
2012
- 2012-07-06 JP JP2012152837A patent/JP2012184273A/ja active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH661662A5 (en) * | 1984-04-16 | 1987-08-14 | Georg L Prof Dr Floersheim | Product for the treatment of the skin and of the connective tissue |
WO1994029452A2 (en) * | 1993-06-09 | 1994-12-22 | Ribozyme Pharmaceuticals, Inc. | Enzymatic rna molecules and their application in the treatment of fibrosis and fibrous tissue disease |
WO1995007711A1 (en) * | 1993-09-14 | 1995-03-23 | Mallinckrodt Medical, Inc. | Therapeutic treatment for inhibiting blood vessel blockage using a polypeptide |
WO1999040929A1 (en) * | 1998-02-12 | 1999-08-19 | The General Hospital Corporation | Methods to potentiate cancer therapies |
Non-Patent Citations (1)
Title |
---|
See also references of WO0228418A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO2002028418A1 (en) | 2002-04-11 |
WO2002028418B1 (en) | 2002-07-18 |
JP2008297313A (ja) | 2008-12-11 |
JP2004510743A (ja) | 2004-04-08 |
AU2002211855B2 (en) | 2007-06-07 |
CA2967607A1 (en) | 2002-04-11 |
CA2425712C (en) | 2017-06-06 |
AU1185502A (en) | 2002-04-15 |
JP2012184273A (ja) | 2012-09-27 |
CA2425712A1 (en) | 2002-04-11 |
NZ525389A (en) | 2009-04-30 |
EP1326627A1 (de) | 2003-07-16 |
IL155250A0 (en) | 2003-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EE200300246A (et) | EP4 retseptori suhtes selektiivsed agonistid osteoporoosi raviks | |
IS6388A (is) | EP4 viðtaka valvís gerandefni í meðhöndluninni á beingisnun | |
NO20032797L (no) | Substituerte pyridoindoler som serotonin agonister og antagonister | |
CY2013011I1 (el) | Μεθοδος χορηγησης διφωσφονικων | |
CY2014003I2 (el) | Φαρμακοτεχνικες μορφες εχινοκανδινης που περιεχουν επιφανειοδραστικα που σχηματιζουν μικκυλιο | |
NO20013183L (no) | Azabicykloalkaner som CCR5-modulatorer | |
ZA200204826B (en) | Preparation of concrete accellerator. | |
MXPA02008402A (es) | Derivados de quinolina como antagonistas alfa-2. | |
PL350347A1 (en) | Method of obtaining non-steroidic modulators of the glucosteroid receptor | |
NO20023770L (no) | Indol-3-ylderivater | |
ZA200305803B (en) | Prevention of diabetes by administration of GnRH antagonists. | |
IL155250A0 (en) | Methods of modulating apoptosis by administration of relaxin agonists or antagonists | |
HK1045684A1 (en) | Biphenyl derivatives as antagonists of the neurokinine-1 receptor. | |
ZA200109206B (en) | Preparation of substituted piperidin-4-ones. | |
MXPA03005405A (es) | Formulacion farmaceutica que contiene tienopirimidinas y antitromboticos, antagonistas de calcio, prostaglandinas o derivados de prostaglandina. | |
HK1045260A1 (en) | Heteroatom-interrupted analogs of 15-hydroxyeicosatetraenoic acid and methods of use. | |
AU2002216245A1 (en) | Methods of modulating toll-related receptor (trr) signaling | |
AU3448601A (en) | Continuous surveyor monitor | |
ATE305925T1 (de) | Positive modulatoren von nicotinrezeptor- agonisten | |
AU2001264900A1 (en) | Pharmaceutical use of fibulin-1 | |
ITRM20020357A0 (it) | Composizione liquida per la somministrazione orale di lorazepam. | |
GB0021927D0 (en) | Use of pharmaceutical combination | |
TW376154U (en) | Laser level of multi-angle directions | |
GB0010124D0 (en) | Administration of beneficial substances | |
DE50104434D1 (de) | Lactam-substituierte pyrazolopyridinderivate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20030430 |
|
AK | Designated contracting states |
Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20040504 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: 7C 07K 14/64 B Ipc: 7A 61P 35/00 B Ipc: 7A 61K 38/22 B Ipc: 7A 61K 38/17 A |
|
17Q | First examination report despatched |
Effective date: 20051228 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20090505 |